Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

NCT02268045 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

BIOLOGICAL: RTXM83
BIOLOGICAL: Mabthera

Sponsor

mAbxience Research S.L.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]